摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Aladorian | 865433-00-7

中文名称
——
中文别名
——
英文名称
Aladorian
英文别名
2-(7-methoxy-3,5-dihydro-2H-1,4-benzothiazepin-4-yl)-2-oxoacetic acid
Aladorian化学式
CAS
865433-00-7
化学式
C12H13NO4S
mdl
——
分子量
267.3
InChiKey
FPWBHFYYVSNIFZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    18
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    92.1
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    参考文献:
    名称:
    Novel agents for preventing and treating disorders involving modulation of the RyR receptors
    摘要:
    本发明提供了式I的新化合物及其盐、水合物、溶剂合物、配合物和前药。本发明还提供了合成式I化合物的方法。此外,本发明还提供了包含式I化合物的制药组合物和使用该制药组合物治疗和预防与细胞中调节钙离子通道功能的RyR受体相关的疾病和疾病的方法。这些疾病和疾病包括,例如,心脏疾病和疾病,骨骼肌疾病和疾病,认知障碍和疾病,恶性高热,糖尿病和婴儿猝死综合征。心脏疾病和疾病包括但不限于心律不齐疾病和疾病;运动引起的心律不齐疾病和疾病;猝死;运动引起的猝死;充血性心力衰竭;慢性阻塞性肺疾病;高血压。心律不齐疾病和疾病包括运动引起的心律不齐疾病和疾病,但不限于心房和心室心律失常;心房和心室颤动;心房和心室快速心律失常;心房和心室快速心跳;儿茶酚胺多形性心室心动过速(CPVT);及其运动引起的变异。骨骼肌疾病和疾病包括但不限于骨骼肌疲劳,运动引起的骨骼肌疲劳,肌萎缩症,膀胱疾病和失禁。认知障碍和疾病包括但不限于阿尔茨海默病,记忆丧失的形式和年龄相关的记忆丧失。
    公开号:
    US20070049572A1
点击查看最新优质反应信息

文献信息

  • PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES
    申请人:Deng Shixian
    公开号:US20090227788A1
    公开(公告)日:2009-09-10
    The invention provides a process for preparing a 2,3,4,5-tetrahydro[1,4]benzothiazepine of formula: by reacting a [2-(acylaminoethyl)thio]arene of formula with an aldehyde or a multimer thereof, and with an acid. The invention also provides for first reacting the [2-(acylaminoethyl)thio]arene with the aldehyde or multimer thereof and a base to form an [N-hydroxymethyl-2-[acylaminoethyl)thio]arene of formula then treating the [N-hydroxymethyl-2-(acylaminoethyl)thio]arene with the acid to form the 2,3,4,5-tetrahydro[1,4]benzothiazepine.
    该发明提供了一种制备2,3,4,5-四氢[1,4]苯并噻吩的方法,通过将式中的[2-(酰胺基乙基)硫]芳烃与醛或其多聚物以及酸反应。该发明还提供了首先将[2-(酰胺基乙基)硫]芳烃与醛或其多聚物以及碱反应以形成式的[N-羟甲基-2-(酰胺基乙基)硫]芳烃,然后用酸处理[N-羟甲基-2-(酰胺基乙基)硫]芳烃以形成2,3,4,5-四氢[1,4]苯并噻吩。
  • Novel agents for preventing and treating disorders involving modulation of the RyR receptors
    申请人:Marks R. Andrew
    公开号:US20070049572A1
    公开(公告)日:2007-03-01
    The present invention provides novel compounds of Formula I and salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells. Such disorders and diseases include, by way of example only, cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome. Cardiac disorder and diseases include, but are not limited to, irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; sudden cardiac death; exercise-induced sudden cardiac death; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure. Irregular heartbeat disorders and diseases include and exercise-induced irregular heartbeat disorders and diseases include, but are not limited to, atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPVT); and exercise-induced variants thereof. Skeletal muscular disorder and diseases include, but are not limited to, skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence. Cognitive disorders and diseases include, but are not limited to, Alzheimer's Disease, forms of memory loss, and age-dependent memory loss.
    本发明提供了Formula I的新化合物及其盐、水合物、溶剂合物、络合物和前药。本发明还提供了合成Formula I化合物的方法。此外,该发明还提供了包含Formula I化合物的药物组合物,以及使用Formula I药物组合物治疗和预防与调节细胞中钙通道功能的RyR受体相关的疾病和疾病的方法。这些疾病包括但不限于心脏疾病、骨骼肌肉疾病、认知障碍和疾病、恶性高热、糖尿病和婴儿猝死综合征。心脏疾病包括但不限于心律不齐疾病、运动诱发的心律不齐疾病、猝死、运动诱发的猝死、充血性心力衰竭、慢性阻塞性肺疾病和高血压。心律不齐疾病和疾病包括运动诱发的心律不齐疾病,但不限于心房和心室心律失常、心房和心室颤动、心房和心室快速心律失常、心房和心室快速心跳、儿茶酚胺多形性心室心动过速(CPVT)及其运动诱发的变体。骨骼肌肉疾病包括但不限于骨骼肌疲劳、运动诱发的骨骼肌疲劳、肌肉萎缩、膀胱疾病和失禁。认知障碍和疾病包括但不限于阿尔茨海默病、各种记忆丧失形式和年龄相关的记忆丧失。
  • [EN] PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES<br/>[FR] PROCÉDÉ POUR PRÉPARER DES BENZOTHIAZÉPINES À PARTIR DE GAMMA-AMINOALKYLBENZÈNES
    申请人:ARMGO PHARMA INC
    公开号:WO2009111463A1
    公开(公告)日:2009-09-11
    The invention provides a process for preparing a 2,3,4,5-tetrahydro[1,4]benzothiazepine of formula: [I] by reacting a [2-(acylaminoethyl)thio]arene of formula [II] with an aldehyde or a multimer thereof, and with an acid. The invention also provides for first reacting the [2-(acylaminoethyl)thio]arene with the aldehyde or multimer thereof and a base to form an [N-hydroxymethyl-2-[acylaminoethyl)thio]arene of formula [III]; then treating the [N-hydroxymethyl-2-(acylaminoethyl)thio]arene with the acid to form the 2,3,4,5-tetrahydro[1,4]benzothiazepine.
    本发明提供了一种制备式为[I]的2,3,4,5-四氢[1,4]苯并噻吩的方法,该方法通过将式[II]的[2-(酰胺基乙基)硫]芳烃与醛或其多聚物以及酸反应而得到。本发明还提供首先将[2-(酰胺基乙基)硫]芳烃与醛或其多聚物以及碱反应以形成式[III]的[N-羟甲基-2-(酰胺基乙基)硫]芳烃;然后用酸处理[N-羟甲基-2-(酰胺基乙基)硫]芳烃以形成2,3,4,5-四氢[1,4]苯并噻吩。
  • METHODS FOR SYNTHESIZING BENZOTHIAZEPINE COMPOUNDS
    申请人:Landry Donald W.
    公开号:US20090292119A1
    公开(公告)日:2009-11-26
    The present invention provides improved methods for synthesizing novel benzothiazepine compounds. In particular, the invention relates to a new method that generally is used to make the substituted 2,3,4,5-tetrahydro-1,4-benzothiazepine compounds of a general formula which then may be used to make many other benzothiazepine compounds.
    本发明提供了改进的合成新型苯并噻吩化合物的方法。具体来说,本发明涉及一种新方法,通常用于制备一般式的取代2,3,4,5-四氢-1,4-苯并噻吩化合物,然后可以用于制备许多其他苯并噻吩化合物。
  • Process for preparing benzothiazepines from gamma-aminoalkylbenzenes
    申请人:Deng Shixian
    公开号:US08618282B2
    公开(公告)日:2013-12-31
    The invention provides a process for preparing a 2,3,4,5-tetrahydro[1,4]benzothiazepine of formula: by reacting a [2-(acylaminoethyl)thio]arene of formula with an aldehyde or a multimer thereof, and with an acid. The invention also provides for first reacting the [2-(acylaminoethyl)thio]arene with the aldehyde or multimer thereof and a base to form an [N-hydroxymethyl-2-[acylaminoethyl)thio]arene of formula then treating the [N-hydroxymethyl-2-(acylaminoethyl)thio]arene with the acid to form the 2,3,4,5-tetrahydro[1,4]benzothiazepine.
    本发明提供了一种制备式为2,3,4,5-四氢[1,4]苯并噻吩的方法,该方法通过将式为[2-(酰胺基乙基)硫代]芳烃与醛或其多聚物以及酸反应来实现。本发明还提供了一种先将[2-(酰胺基乙基)硫代]芳烃与醛或其多聚物和碱反应以形成式为[N-羟甲基-2-(酰胺基乙基)硫代]芳烃,然后用酸处理[N-羟甲基-2-(酰胺基乙基)硫代]芳烃以形成2,3,4,5-四氢[1,4]苯并噻吩。
查看更多

同类化合物

齐瑞索韦 马来酸地尔硫卓 贝匹斯汀 苯甲醇,-α--(1-氨基-2-丙烯基)-(9CI) 硫西新 盐酸地尔硫卓O-去乙酰化物 盐酸地尔硫卓 盐酸地尔硫卓 氯噻平 氟水杨基<邻羟苄基>醛 尼克噻嗪 富马酸喹硫平 奎硫平去羟乙基杂质 奎硫平乙醚(富马酸) 奎硫平DBTO砜 地尔硫卓肾上腺素 地尔硫卓杂质8 地尔硫卓杂质5 地尔硫卓杂质4 地尔硫卓杂质 地尔硫卓EP杂质A 地尔硫卓-d6 地尔硫卓 喹硫平砜 喹硫平杂质E 喹硫平杂质DHCl 喹硫平亚砜 喹硫平二聚体 喹硫平EP杂质S盐 喹硫平 N-氧化物 喹硫平 哌苯硫氮杂卓 哌嗪,3,3-二甲基-1-(1-甲基乙基)-(9CI) 去乙酰基地尔硫卓N-氧化物 去乙酰地尔硫卓 去乙酰-O-去甲基地尔硫卓 克仑硫卓 倍氯米松杂质D 二苯并[b,f]咪唑并[1,2-d][1,4]硫氮杂卓 二苯并[b,f][1,4]硫氮杂卓-11-胺 二苯并[b,f][1,4]硫氮杂卓-11-[10H]酮 二苯并(b,f)-1,2,4-三唑并(4,3-d)(1,4)硫氮杂卓-6-胺 [5-(2-二甲基氨基乙基)-8-甲基-2-(4-甲基苯基)-4-氧代-2,3-二氢-1,5-苯并硫氮杂卓-3-基]乙酸酯 [5-(2-二甲基氨基乙基)-2-(4-甲氧基苯基)-4-氧代-2,3-二氢-1,5-苯并硫氮杂卓-3-基]乙酸酯 [2H6]-乙酰基地尔硫卓 [1,3]噻唑并[4,5-I][1,5]苯并硫氮杂卓 [(2S,3S)-3-乙酰氧基-2-(4-乙氧基苯基)-4-氧代-2,3-二氢-1,5-苯并硫氮杂卓-5-基]-乙基-二甲基铵碘化物 [(2S,3S)-2-(4-甲氧基苯基)-5-[2-(甲基-丙-2-基氨基)乙基]-4-氧代-2,3-二氢-1,5-苯并硫氮杂卓-3-基]乙酸酯 N-去甲地尔硫卓马来酸盐 N,N-二去甲基地尔硫卓盐酸盐